Medical Device News Magazine

Sorrento Therapeutics, Inc. announces a $4.6 Million U.S. Government Contract from the NIAID for a Sensitive, Reusable, and Rapid Diagnostic Platform for Pandemic Preparedness

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • At the conclusion of the contract, Sorrento and Virex Health intend to deliver a rapid, sensitive, accurate and scalable diagnostic capable of being readily deployed in response to an emergent or reemergent threat.

Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) today announces it has been awarded a $4.6 million contract from the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health (NIH) for the development of in vitro diagnostics for biodefense, antimicrobial resistant infections and emerging infectious diseases. The award shows NIAID’s support for the development of promising quantitative diagnostics technologies for detection of signatures from biothreat pathogens as well as pathogens causing emerging or reemerging infectious diseases, and for pandemic preparedness.

The purpose of the contract is to develop a diagnostic platform for rapid and sensitive detection of proteins and other biomolecules that improves existing rapid testing devices (RTDs). Current diagnostic RTDs have long development timelines and low clinical sensitivity. Sorrento and Virex Health, LLC (Virex Health), a wholly owned subsidiary of Sorrento, plan to develop an adaptable diagnostic platform which is highly sensitive and cost-effective for multiple pathogens. This approach leverages the expertise of Sorrento to rapidly select and produce highly specific antibodies from its proprietary G-MAB™ library targeting viral and bacterial antigens, combined with a chemical detection approach and the existing infrastructure of the glucometer industry.

Virex Health has developed a proprietary technology for electrochemical detection of bioanalytes (virus, proteins, and small molecules) using the similar electronic device requirements employed in reusable glucometers and has reformulated the chemistry contained on the test strip to detect pathogens. In so doing, Virex Health leverages an existing infrastructure that produces tens of millions of devices per year. The objective is to address the needs of rapid detection for biodefense and new emerging infectious disease preparedness. At the conclusion of the contract, Sorrento and Virex Health intend to deliver a rapid, sensitive, accurate and scalable diagnostic capable of being readily deployed in response to an emergent or reemergent threat. “Once the diagnostic platform is developed, our unique approach can be quickly transferred to other pathogens and deployed when needed on a large scale,” said Scott Schaus, Ph.D., Co-founder and Chief Technology Officer for Virex Health.

“We are pleased to accept this award and collaboration with the U.S. Government to ensure that, as a society, we are better prepared for the next pandemic. This award validates our unique approach of combining antibody development and electrochemical-based diagnostics for a rapid response to save lives and manage infectious disease outbreaks,” stated Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics.

“This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93023C00024”.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.